Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Correspondence

Ibrutinib for Chronic Lymphocytic Leukemia

To the Editor: It is not surprising that Burger et al. (Dec. 17 issue)1 report positive results in the Study of Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia (RESONATE-2), a randomized trial of ibrutinib versus chlorambucil in older patients with chronic lymphocytic leukemia (CLL). Chlorambucil has served as a comparator in trials of bendamustine, alemtuzumab, ofatumumab, and obinutuzumab, and longer durations of progression-free survival have been reported with each agent.25 In addition, these trials have shown longer durations of overall survival with the use of ibrutinib and obinutuzumab.1,2We reviewed our experience in the Connect . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Print Subscriber? Activate your online access.